相关实验视频

Updated: Aug 1, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

对CTLA4促进体变异的功能分析及其对结直肠癌免疫疗法的可能影响

Mariana Angulo-Aguado¹, Sarah Orjuela-Amarillo¹, Julián Francisco Mora-Jácome¹

¹Universidad Del Rosario, School of Medicine and Health Sciences, Center for Research in Genetics and Genomics (CIGGUR), Institute of Translational Medicine (IMT), Bogotá, Colombia.

Frontiers in medicine

|August 21, 2023

概括

在CTLA4 (c.-319C>T) 中的一种特定的遗传变异与增加结直肠癌易感性有关. 这种变异可能通过改变基因表达和T细胞调节来增强瘤免疫逃避.

科学领域:

遗传学是一个遗传学.
免疫学免疫学免疫学
在瘤学瘤学.

背景情况:

大肠直肠癌 (CRC) 是癌症死亡的主要原因.
瘤的免疫逃避在CRC的启动和进展中至关重要.
CTLA4是一种T细胞调节剂,与CRC的发展和治疗反应有关.

研究的目的:

调查CTLA4 c.-319C>T变种与CRC敏感性之间的关联.
探索这种变异对CTLA4基因表达和T细胞调节的功能影响.

主要方法:

病例控制研究 (98名CRC患者,424名对照).
对CTLA4 c.-319C>T变异的基因定型 (rs5742909).
在分析 (Genomatix),酶记者基因测定和电泳性移动转移测定 (EMSA).

主要成果:

在CTLA4c.-319C>T和CRC敏感性之间发现了显著的关联 (p=0.023,OR=1.89).
确定了LEF1和TCF7作为与CTLA4c.-319C等位基因结合的转录因子.
功能性测试表明基因表达和TCF7相互作用的等位基因特异性差异.

结论:

CTLA4 c.-319C>T变异与CRC敏感性增加有关.
这种变异可能会在转录上改变CTLA4基因表达.
这种改变可能导致增强的T细胞抑制和瘤免疫逃避.

关键词:

CTLA4 CTLA4 在线播放生物标志物生物标志物结肠直肠癌是什么意思免疫性瘤逃避免疫性瘤逃避免疫疗法免疫疗法

更多相关视频

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)

Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)

Published on: June 27, 2025

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...